Wednesday, February 10, 2016

ARMO BioSciences Takes $50M

Redwood City-based ARMO BioSciences, which is developing immunotherapy drugs, announced today that it has raised $50M in a Series C financing. The financing came from Kleiner Perkins Caufield & Byers (KPCB), OrbiMed, DAG Ventures and NanoDimension, plus HBM Healthcare Investments, GV (formerly Google Ventures), Celgene Corporation, Industrial Investors Group and private investment funds advised by Clough Capital Partners L.P. ARMO's products are targeted at the treatment of cancer. More information »